# Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines

> **NCT02718118** · PHASE4 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 60 (actual)

## Conditions studied

- Glabellar Lines
- Wrinkles

## Interventions

- **DEVICE:** Dysport reconstituted at 1.5 mL (0.05 mL/injection)
- **DEVICE:** Dysport reconstituted at 2.5 mL (0.08 mL/injection)

## Key facts

- **NCT ID:** NCT02718118
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02718118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02718118, "Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02718118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*